NOW LIVE! Just presented at #MHNCS26 - We discuss the initial report of NRG-HN009 for advanced head & neck cancer in this podcast episode as well as the currently enrolling NRG-HN010 trial in HER2-expressing salivary gland cancer. Tune in: www.NRGOncology.org/Podcast
A positive readout from the SINERGY trial, a prospective Phase 2 study in recurrent or metastatic head and neck squamous cell carcinoma, was recently presented in an oral plenary session at the 2026 Multidisciplinary Head and Neck Cancers Symposium. #MHNCS26
Read more: https://ow.ly/gsZ350Ylky9
#MHNCS26 phase II trial of the trop-2 / Topo 1 ADC, Sacituzumab Govitecan in recurrent post PD1 metastatic #HNSCC presented as a TIP #MedIQMHNCS26
#MHNCS26 encouraging results of NBTXR3 with SBRT in recurrent post PD1 failure R/M #HNSCC with ORR exceeding 60% in this early data #MedIQMHNCS26
#MHNCS26 AHEAD MERIT pivotal phase II / III trial of HPV 16 E6,E7 mRNA immunotherapy : BNT 113 + Pembro vs Pembro in RM PDL1 + HPV 16 #HNSCC, TIP #MedIQMHNCS26
#MHNCS26 Ficlatuzumab + Cetuximab vs Cetuximab for second line RM # HNSCC, pivotal phase III trial relying on overcoming EGFR resistance through targeting met, FIERCE HN trial, #MedIQMHNCS26
#MHNCS26 updates from KN689 as to surgical data; EFS correlates with mPR; surgical rate is similar in both arms, #MedIQMHNCS26 #HNSCC
#MHNCS26 predictive and prognostic IO markers to be analyzed for R/M #HNSCC in the Phoenix tissue procurement study, so far 52 patients enrolled; a TIP poster session #MedIQMHNCS26
#MHNCS26 ongoing Evolve trial is a global study of Volrustamab vs observation post definitive Chemo RT in LA #HNSCC updated in a TIP poster session #MedIQMHNCS26
#MHNCS26 preoperative SC Amivantamab shows tolerability and encouraging responses with ORR of 46% in this cohort of pre and post Ami + Pembro resectable HPV - #HNSCC #MedIQMHNCS26
#MHNCS26 the only STAT3 targeted ASO shows no increase in response compared to single agent Pembro in 1st line randomized PEMDA Denvatirsen Pembro vs Pembro phase II study #MedIQMHNCS26 #HNSCC
#MHNCS26 encouraging responses with Ficerafusp Alfa 2000 mg Q 2 weeks and Pembro 400 Q 6 in 1st line RM HPV - HNSCC , ORR 48% CR 26% #MedIQMHNCS26 #HNSCC
Encouraging results with ORR 56% CR 10% shrinkage of tumor in 82% in Origami 4 Amivantamab + Pembro cohort #MHNCS26
#MedIQMHNCS26 #HNSCC
Thank you to Dr. Nabil Saba for his live updates on the latest clinical study data for several investigational therapies for R/M HNSCC, shared live from #MHNCS26. Check out this thread for highlights.
#MedIQMHNCS26
NOW LIVE! Just presented at #MHNCS26 - We discuss the initial report of NRG-HN009 for advanced head & neck cancer in this podcast episode as well as the currently enrolling NRG-HN010 trial in HER2-expressing salivary gland cancer. Tune in: www.NRGOncology.org/Podcast
What's going on in the world of head and neck cancer? On Feb. 20th, after the ASTRO #MHNCS26 initial result for NRG-HN009, we will release a new episode interviewing study PI, Dr. Harari. Also we will hear about NRG's HN010 for salivary cancer with study PI, Dr. Ho. www.NRGOncology.org/Podcast
What's going on in the world of head and neck cancer? On Feb. 20th, after the ASTRO #MHNCS26 initial result for NRG-HN009, we will release a new episode interviewing study PI, Dr. Harari. Also we will hear about NRG's HN010 for salivary cancer with study PI, Dr. Ho. www.NRGOncology.org/Podcast
Join SITC and engage with experts through interactive case discussions at the 2026 Multidisciplinary Head and Neck Cancers Symposium Feb. 19-21, in Palm Desert, CA. SITC members, use the code HNC26SITC to receive access to the co-sponsor member rate. Learn more: https://ow.ly/ngx550XTtum
#MHNCS26
